Ali Can Albaz, *Oktay Üçer
Department of Urology, Faculty of Medicine, Celal Bayar University, Manisa, Turkey
*Correspondence to email@example.com
Disclosure: The authors have declared no conflicts of interest.
Received: 17.01.17 Accepted: 26.04.17
Citation: EMJ. 2017;2:63-70.
Peyronie’s disease (PD), which is characterised by fibrous plaque formation in the tunica albuginea of the penis, is associated with pain, erectile dysfunction, and anatomical malformations that negatively affect the quality of life of afflicted men. The optimum medical therapy for PD has not yet been identified. In the last 5 years, commonly used oral medications have been replaced by intralesional therapies. Intralesional collagenase Clostridium histolyticum is the only US Food and Drug Administration (FDA) approved treatment for PD. Minimally invasive intralesional therapies and surgical intervention form the basis of contemporary therapy for this disorder. These therapeutic options, along with selected portions of the guidelines, are explored in this review. The objective is to describe the current state of practice for each of the most commonly used, as well as several developing, treatment modalities of PD.
This article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.